Kastamonu University, which has made a name for itself in medicine, has taken an important step with its studies on cancer treatment.
Under the direction of Sedat Gökmen from Kastamonu University, Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, Assoc.Prof.Dr. İrfan Çınar from Faculty of Medicine, Department of Medical Pharmacology, Assoc.Prof.Dr.Musa Tatar from Faculty of Veterinary Medicine, Department of Histology and Embryology, and Assoc.Prof.Dr. Kıymet Kübra Tüfekçi from Faculty of Medicine, Department of Histology and Embryology were researchers. The project titled “[Gly14]-Humanin Protective Effects of [Gly14]-Humanin on Cisplatin-induced Neurotoxicity in Vitro and In Vivo” was entitled to receive 74,998 TL of support for 1 year within the scope of TÜBİTAK 1002-A Rapid Support Module.
In the research, which will make an important contribution to cancer research in the future, the protective effects of [Gly14]-Humanin, which has a peptide structure to prevent cisplatin toxicity used for the treatment of many solid cancer types, will be investigated both in cell culture and animal experiments.
The results of the project, which aims to contribute to the development of alternative strategies to reduce or prevent the side effects of drugs used in cancer treatment, are expected to make important contributions in the field of targeted cancer therapy.
Our Rector, Prof. Dr. Ahmet Hamdi Topal, congratulated our academicians who took part in this project and study and expressed his gratitude to the President of the Council of Higher Education, Prof. Dr. Erol Özvar, and the members of the Council of Higher Education for their support. In addition, our Rector thanked Prof. Dr. Hasan Mandal, President of TÜBİTAK, for his encouraging approach to our institution in project studies.
